Noema Pharma
Noema is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
noemapharma.com
Related News
Noema Pharma Appoints Michael Samar as Chief Financial Officer
Noema Pharma appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
Noema Pharma announces first patient dosed in Phase 2a Study of NOE-115, a first-in-class investigational therapy for the treatment of vasomotor symptoms and additional symptoms associated with menopause
Noema Pharma appoints Ilise Lombardo, M.D., as Chief Executive Officer
Noema Pharma, founded by Sofinnova Partners, raises CHF 103 million (USD112million) in Series B financing
Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia
Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study
Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder
Noema Pharma appoints Michael Gutch as Chief Financial Officer
Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b study of trigeminal neuralgia therapy
Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.